We are monitoring the impact of COVID-19 on MEA Bladder Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 1090
Share on
Share on

Middle East and Africa Bladder Cancer Therapeutics Market Research Report – Segmented By Type, Treatment and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth and Forecast | 2019 – 2024

Pulished: August, 2019
ID: 1090
Pages: 133

MEA Bladder Cancer Therapeutics Market Size & Growth

The size of the Bladder Cancer Therapeutics market in the Middle East and Africa is expected to reach USD 29.27 million by 2024 from USD 23.61 million in 2019, growing at a CAGR of 4.39% from 2019 to 2024

Bladder cancer is aroused due to malignancy of urinary bladder lining with epithelial cells. The bladder is an organ present at the lower part of the abdomen and stores urine. Over developing of these epithelial cells results in blabber cancer and it can be of many types such as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. At the present number of therapies have been evolved for the management of bladder cancers include chemotherapies, immunotherapies, surgeries, radiation therapies, and other therapies.

The growing number of the aging population, presence of the huge number of bladder cancer patients, and increasing involvement of public & private organizations to support cancer registries and cancer research are driving the growth of the bladder cancer therapeutics market in Middle-East & Africa. However, lack of awareness among cancer patients about advanced therapies and underdeveloped healthcare infrastructure is limiting the growth of the bladder cancer therapeutics market in the Middle-East & Africa.

This research report is segmented & sub-segmented the market into the following categories:

  • By Type: Transitional Cell Bladder Cancer, Non-Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder and Rare Bladder Cancers
  • By Country: KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Companies like Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.) are playing a leading role in the MEA Bladder Cancer Therapeutics Market.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Transitional Cell Bladder Cancer    

                                5.1.2 Non Muscle Invasive/Superficial Bladder Cancer     

                                5.1.3 Invasive Bladder Cancer    

                                5.1.4 Squamous Cell Bladder Cancer       

                                5.1.5 Adenocarcinoma of the Bladder    

                                5.1.6 Rare Bladder Cancers         

                5.2 By Treatment                            

                                5.2.1 Surgery    

                                                5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)

                                                5.2.1.2 Cystectomy

                                                5.2.1.3 Urinary Diversion

                                5.2.2 Chemotherapy     

                                5.2.3 Immunotherapy   

                                5.2.4 Radiation Therapy

                                5.2.5 Intravesical Therapy           

6. Geographical Analysis                                              

                6.1 Middle East & Africa               

                                6.1.1 Introduction           

                                6.1.2 Middle-East            

                                6.1.3 Africa        

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Sanofi S.A. (France)                 

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 GlaxoSmithKline plc (U.K.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 AstraZeneca plc (U.K.)                           

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Celgene Corporation (U.S.)               

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Middle East & Africa Bladder Cancer Therapeutics Market By Region, From 2019 - 2024 ( USD Million )
  2. Middle East & Africa Bladder Cancer Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  3. Middle East & Africa Transitional Cell Bladder Cancer Market By Region, From 2019 - 2024 ( USD Million )
  4. Middle East & Africa Non Muscle Invasive/Superficial Bladder Cancer Market By Region, From 2019 - 2024 ( USD Million )
  5. Middle East & Africa Invasive Bladder Cancer Market By Region, From 2019 - 2024 ( USD Million )
  6. Middle East & Africa Squamous Cell Bladder Cancer Market By Region, From 2019 - 2024 ( USD Million )
  7. Middle East & Africa Adenocarcinoma of the Bladder Market By Region, From 2019 - 2024 ( USD Million )
  8. Middle East & Africa Rare Bladder Cancers Market By Region, From 2019 - 2024 ( USD Million )
  9. Middle East & Africa Bladder Cancer Therapeutics Market By Treatment, From 2019 - 2024 ( USD Million )
  10. Middle East & Africa Bladder Cancer Surgery Market By Region, From 2019 - 2024 ( USD Million )
  11. Middle East & Africa Bladder Cancer Chemotherapy Market By Region, From 2019 - 2024 ( USD Million )
  12. Middle East & Africa Bladder Cancer Immunotherapy Market By Region, From 2019 - 2024 ( USD Million )
  13. Middle East & Africa Bladder Cancer Radiation Therapy Market By Region, From 2019 - 2024 ( USD Million )
  14. Middle East & Africa Bladder Cancer Intravesical Therapy Market By Region, From 2019 - 2024 ( USD Million )
  15. Middle-East Bladder Cancer Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  16. Middle-East Bladder Cancer Therapeutics Market By Treatment, From 2019 - 2024 ( USD Million )
  17. Africa Bladder Cancer Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  18. Africa Bladder Cancer Therapeutics Market By Treatment, From 2019 - 2024 ( USD Million )
  19. Middle East & Africa Bladder Cancer Surgery Market By Type, From 2019 - 2024 ( USD Million )
  20. Middle East & Africa Transurethral Bladder Tumor Resection (TURBT) Market By Region, From 2019 - 2024 ( USD Million )
  21. Middle East & Africa Bladder Cancer Cystectomy Market By Region, From 2019 - 2024 ( USD Million )
  22. Middle East & Africa Bladder Cancer Urinary Diversion Market By Region, From 2019 - 2024 ( USD Million )
  23. Middle-East Bladder Cancer Surgery Market By Type, From 2019 - 2024 ( USD Million )
  24. Africa Bladder Cancer Surgery Market By Type, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample